Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication

Internal Medicine

Volumn 54, Issue 7, 2015, Pages 703-710

  He, Lei ^a   Deng, Tao ^a   Luo, Hesheng ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Concomitant therapy; Eradication; Helicobacter pylori; Hybrid therapy; Meta analysis; Sequential therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ARTICLE; COMPARATIVE EFFECTIVENESS; CONCOMITANT THERAPY; CONFIDENCE INTERVAL; DISEASE ERADICATION; HELICOBACTER INFECTION; HUMAN; HYBRID THERAPY; MEDICAL PROCEDURES; META ANALYSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEQUENTIAL THERAPY; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; STATISTICAL ANALYSIS;

ANTI-BACTERIAL AGENTS; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 84926379782     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.3442     Document Type: Article

References (36)

1. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 362: 1597-1604, 2010.
2. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 61: 646-664, 2012.
3. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24: 1587-1600, 2009.
4. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 34: 1255-1268, 2011.
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153, 2010.
6. Zullo A, Rinaldi V, Winn S, et al. A new highly effective shortterm therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 14: 715-718, 2000.
7. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 104: 3069-3079, 2009.
8. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin, metronidazole, omeprazole, clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 3: 54-58, 1998.
9. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 33: 640-645, 1998.
10. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 5: 23-34, 2012.
11. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a random ized controlled trial (MACLOR study). Arch Intern Med 162: 153-160, 2002.
12. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 16: 139-145, 2011.
13. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. 14-day, high-dose acid suppression, non-bismuth quadruple therapies (hybrid vs. concomitant) for Helicobacter pylori infection: a randomized trial [abstract]. Gastroenterology 144: S-53, 2013.
14. Ang TL, Fock KM, Ang D. A randomized controlled trial of triple therapy versus sequential therapy versus concomitant therapy as first line treatment for H. pylori Infection [abstract]. Gastroenterology 144: S-53, 2013.
15. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 63: 748-752, 2014.
16. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomized trial. Lancet 378: 507-514, 2011.
17. Huang YK, Wu MC, Wang SS, et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 13: 232-238, 2012.
18. Lim JH, Lee DH, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 18: 180-186, 2013.
19. McNicholl AG, Marin AC, Molina-Infante J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 63: 244-249, 2014.
20. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 145: 121-128.e1, 2013.
21. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 18: 129-134, 2013.
22. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 8: 36-41, 2010.
23. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 37: 647-650, 2013.
24. Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 143: 55-61, 2012.
25. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, 1996.
26. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826, 1997.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986.
28. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959.
29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101, 1994.
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 315: 629-634, 1997.
31. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 148: 923-931, 2008.
32. Yoon H, Lee DH, Kim N, et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 28: 1801-1809, 2013.
33. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: fourdrug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter 14: 109-118, 2009.
34. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 19: 409-414, 2010.
35. Zullo A, Perna F, Hassan C, et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 25: 1429-1434, 2007.
36. Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 18: 274-279, 2013.